Petronella Muresan

发表

Determinants of Vaccine Immunogenicity in HIV-Infected Pregnant Women: Analysis of B and T Cell Responses to Pandemic H1N1 Monovalent Vaccine

M. Levin, M. Abzug, S. Nachman, 2015, PloS one.

Effect of Maternal Vaccination on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Study of PCV-10, PPV-23 or Placebo Administered during Pregnancy.

F. Bone, D. Goldblatt, S. Pelton, 2021 .

Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.

J. Mascola, G. Theron, B. Graham, 2021, The Journal of infectious diseases.

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

J. Mascola, J. Safrit, L. Mofenson, 2020, The Journal of infectious diseases.

Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women

M. Levin, M. Abzug, S. Nachman, 2015, AIDS research and human retroviruses.

High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)

S. Spector, G. Siberry, E. Handelsman, 2013, Human vaccines & immunotherapeutics.

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children

R. Karron, S. Spector, E. Barr, 2018, The Journal of infectious diseases.

Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.

M. Levin, E. Handelsman, M. Abzug, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of 2009 pH 1 N 1 Vaccination in HIV-Infected Pregnant Women

M. Levin, E. Handelsman, M. Abzug, 2013 .

Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial.

D. Goldblatt, S. Pelton, J. Pinto, 2021, The lancet. HIV.

Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children

E. Barr, L. Collins, U. Buchholz, 2020 .

Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.

J. Lambert, S. Gurunathan, G. Tomaras, 2005, The Journal of infectious diseases.

Pharmacokinetics and Safety of a New Paediatric Fixed-Dose Combination of Zidovudine/Lamivudine/Nevirapine in HIV-Infected Children

L. Aurpibul, R. Yogev, E. Capparelli, 2011, Antiviral therapy.

A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine: Pharmacokinetics and Safety Compared With the Individual Liquid Formulations in Human Immunodeficiency Virus-infected Children in Thailand

W. Prasitsuebsai, R. Yogev, E. Capparelli, 2010, The Pediatric infectious disease journal.

Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.

W. Borkowsky, A. Weinberg, J. Read, 2008, The Journal of infectious diseases.

HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers

J. Lambert, S. Gurunathan, G. Tomaras, 2006, AIDS.

Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy

T. Greenough, S. Ray, D. Persaud, 2009, Journal of Virology.

Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia.

W. Borkowsky, R. Yogev, E. Capparelli, 2008, AIDS research and human retroviruses.

Characterization of Functional Antibody and Memory B-Cell Responses to pH1N1 Monovalent Vaccine in HIV-Infected Children and Youth

S. Spector, S. Nachman, Donna J. Curtis, 2015, PloS one.

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

W. Borkowsky, S. Spector, G. Siberry, 2013, Journal of the Pediatric Infectious Diseases Society.

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

S. Spector, R. Yogev, G. Siberry, 2012, The Journal of infectious diseases.

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Jerome H. Kim, H. Liao, B. Haynes, 2014, The Journal of infectious diseases.

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

T. Greenough, P. Barker, D. Persaud, 2008, Vaccine.

Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402.

J. Sleasman, D. Wara, S. Pahwa, 2007, Journal of Allergy and Clinical Immunology.

Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children

M. Levin, S. Douglas, J. Pitt, 2003, AIDS.

Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.

R. Karron, S. Spector, P. Collins, 2020, American journal of respiratory and critical care medicine.

Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children

R. Karron, S. Spector, E. Barr, 2018, The Journal of infectious diseases.

Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children.

R. Karron, E. Barr, P. Collins, 2020, The Journal of infectious diseases.

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir

T. Greenough, A. Blackford, D. Persaud, 2011, AIDS.

Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children.

R. Karron, S. Spector, E. Barr, 2019, The Journal of infectious diseases.

Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV Seronegative Children.

R. Karron, E. Barr, P. Collins, 2022, The Journal of infectious diseases.

Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.

W. Borkowsky, G. Fouda, S. Permar, 2018, Vaccine.

Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.

W. Borkowsky, R. Yogev, L. Frenkel, 2008, Vaccine.

Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated

R. Karron, E. Barr, Bhagvanji Thumar, 2019, Open Forum Infectious Diseases.

Effect of Maternal Vaccination of PCV-10, PPV-23 or Placebo on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Clinical Trial.

E. Joao, J. Pilotto, N. Chakhtoura, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.